William G Wierda, MD, University of Texas MD Anderson Cancer Center

home / authors / william-g-wierda-md-university-of-texas-md-anderson-cancer-center

Articles

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

William G Wierda, MD, University of Texas MD Anderson Cancer Center
October 21st 2021

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

Read More

CLL: Prognostic Markers

CLL: Prognostic Markers

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 20th 2021

An overview of prognostic models in chronic lymphocytic leukemia (CLL).

Read More

Prognostic Factors in Chronic Lymphocytic Leukemia

Prognostic Factors in Chronic Lymphocytic Leukemia

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 20th 2021

A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Read More

Molecular Testing for Newly Diagnosed CLL

Molecular Testing for Newly Diagnosed CLL

William G Wierda, MD, University of Texas MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;Ehab Atallah, MD, Medical College of Wisconsin;Steven Coutre, MD, Stanford University Medical Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center;Jennifer Woyach, MD, Ohio State University
July 13th 2021

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need